DeepMed Research

Icosapent

Generic Name: Icosapent

Brand Names: Animi-3 With Vitamin D

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₃₀O_₂

CAS Number: 10417-94-4

Unique Ingredient Identifier: AAN7QOV9EA

Background: Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families.

Indication: EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.

Associated Therapies: Dietary and Nutritional Therapies

Clinical Trials

Targeting Vascular INflammation in Patients with Community-Acquired Pneumonia

Phase 3

Not yet recruiting

Conditions: Inflammation
Community Acquired Pneumonia (CAP)
Inflammation Plaque, Atherosclerotic

Interventions: Drug: Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
Drug: Placebo

First Posted Date: 2024-11-29

Last Posted Date: 2024-12-05

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 168

Registration Number: NCT06710080

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Differential Thrombogenesis by EPA and DHA Mediated by HDL

Early Phase 1

Not yet recruiting

Conditions: Lipid Metabolism Disorders

Interventions: Drug: DHA
Drug: EPA

First Posted Date: 2024-07-10

Last Posted Date: 2024-12-17

Lead Sponsor: The Miriam Hospital

Target Recruit Count: 80

Registration Number: NCT06494488

Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases

Completed

Conditions: Colon Cancer Liver Metastasis

Interventions: Drug: Icosapent Ethyl Oral Capsule
Other: Placebo

First Posted Date: 2020-12-24

Last Posted Date: 2024-12-04

Lead Sponsor: University of Leeds

Target Recruit Count: 81

Registration Number: NCT04682665

Locations: 🇬🇧
St James's University Hospital, Leeds, United Kingdom
🇬🇧
University of Liverpool, Liverpool, United Kingdom

The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk

Phase 4

Completed

Conditions: Cardiovascular Diseases
Cardiovascular Risk Factor
Triglycerides High
Diabetes Mellitus, Type 2

Interventions: Drug: Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]

First Posted Date: 2020-09-24

Last Posted Date: 2024-04-02

Lead Sponsor: Canadian Medical and Surgical Knowledge Translation Research Group

Target Recruit Count: 70

Registration Number: NCT04562467

Locations: 🇨🇦
The Oshawa Clinic, Oshawa, Ontario, Canada
🇨🇦
Diagnostic Assessment Centre, Scarborough, Ontario, Canada
🇨🇦
Langstaff Medical Clinic, Vaughan, Ontario, Canada

PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial

Phase 3

Completed

Conditions: COVID19

Interventions: Drug: Icosapent ethyl (IPE)
Drug: Placebo

First Posted Date: 2020-07-07

Last Posted Date: 2021-09-17

Lead Sponsor: Estudios Clínicos Latino América

Target Recruit Count: 4093

Registration Number: NCT04460651

Locations: 🇦🇷
Instituto de Investigaciones Clínicas - Rosario, Rosario, Santa Fe, Argentina

Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia

Phase 3

Completed

Conditions: Hypertriglyceridemia

Interventions: Drug: Icosapent

First Posted Date: 2020-01-09

Last Posted Date: 2021-08-23

Lead Sponsor: Mochida Pharmaceutical Company, Ltd.

Target Recruit Count: 120

Registration Number: NCT04221217

Locations: 🇯🇵
Mochida Investigational sites, Tokyo, Japan

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Phase 1

Terminated

Conditions: Chronic Myeloid Leukemia, Chronic Phase

Interventions: Drug: Eicosapentaenoic Acid
Drug: Tyrosine kinase inhibitor

First Posted Date: 2019-07-05

Last Posted Date: 2022-07-01

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 1

Registration Number: NCT04006847

Locations: 🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States

Vascepa to Accelerate Lipoprotein Uptake and Elimination

Phase 1

Completed

Conditions: Lipid Disorder
Triglycerides High
Dyslipidemias

Interventions: Drug: Icosapent Ethyl 1000 MG [Vascepa]

First Posted Date: 2019-03-21

Last Posted Date: 2021-11-11

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 20

Registration Number: NCT03885661

Locations: 🇺🇸
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Efficacy of MND-2119 in Participants With Hypertriglyceridemia

Phase 3

Completed

Conditions: Hypertriglyceridemia

Interventions: Drug: Icosapent (MND-2119)
Drug: Icosapent (EPADEL CAPSULES 300)

First Posted Date: 2018-10-02

Last Posted Date: 2019-08-01

Lead Sponsor: Mochida Pharmaceutical Company, Ltd.

Target Recruit Count: 580

Registration Number: NCT03693131

Locations: 🇯🇵
Mochida Investigational sites, Tokyo, Japan

Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO]

Phase 4

Conditions: Coronary Artery Disease
Angina Pectoris

Interventions: Drug: EPA and rosuvastatin
Drug: High dose rosuvastatin

First Posted Date: 2018-09-05

Last Posted Date: 2018-09-18

Lead Sponsor: Kobe University

Target Recruit Count: 75

Registration Number: NCT03657758

Locations: 🇯🇵
Kobe University Graduate School of Medicine, Department of Cardiology, Kobe, Hyogo, Japan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy